Effects of β2-agonists on resident and infiltrating inflammatory cells

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 6 SUPPL., 2002, Pages

  Johnson, Malcolm ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Combination therapy; Corticosteroid; Inflammatory cells; 2 agonists

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; ISOPRENALINE; SALBUTAMOL; SALMETEROL; BETA 2 ADRENERGIC RECEPTOR; GLUCOCORTICOID;

ANTIINFLAMMATORY ACTIVITY; BASOPHIL; BETA ADRENERGIC STIMULATION; CELL ACTIVATION; CELL COUNT; CELL SURVIVAL; CONFERENCE PAPER; EOSINOPHIL; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LUNG LAVAGE; MAST CELL; MONOCYTE; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; T LYMPHOCYTE; ASTHMA; CELLULAR IMMUNITY; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; LUNG; MONONUCLEAR CELL; REVIEW;

ADRENERGIC BETA-AGONISTS; ASTHMA; GLUCOCORTICOIDS; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTES, MONONUCLEAR; LUNG; MAST CELLS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0036907527     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.129430     Document Type: Conference Paper

References (57)

1. Bousquet J, Jeffery PK, Busse W, Johnson M, Vignola AM. Asthma: From bronchoconstriction to airway inflammation and remodelling. Am J Respir Crit Care Med 2000;161:1720-45.
2. 2-adrenoceptor agonists. In: Busse W, Holgate ST, eds. Asthma and Rhinitis 2. Blackwell: Oxford Press; 2000. p. 1541-57.
3. Butchers PR, Vardey CJ, Johnson M. Salmeterol: A potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991;104:672-6.
4. Remy FJ, Dimitry EA, Jaffe JS, Raible DG, Post TJ, Glaum M, et al. Isoproterenol and salmeterol-induced attenuation of interleukin-5 mRNA and protein from anti-IgE challenged human lung fragments. Am J Respir Crit Care Med 1995;151:A388.
5. 2-agonists: Inhibition of TNF-α release from human mast cells. J Allergy Clin Immunol 1997;100:825-31.
6. 2-adrenoceptors agonists. In: Barnes PJ, editor. New Drugs for Asthma, vol 2. London: IBC Technical Services; 1992. p. 18-32.
7. Howarth PH, Durham SR, Lee TH, Kay AB, Church MK, Holgate ST, et al. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator response to allergen bronchial provocation in asthma. Am Rev Respir Dis 1982;132:986-92.
8. Boulet L-P, Turcotte H, Boutet M, Dubé J, Gagnon M, Laviolette M. Influence of salmeterol on chronic and allergen-induced airway inflammation in mild allergic asthma: A pilot study. Curr Ther Res 1997;58:240-59.
9. Proud D, Reynolds CJ, Lichtenstein LM, Kagey-Sobotka A, Togias A. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998;28:868-75.
10. 2-adrenergic receptor. J Biol Chem 1997;272:7338-44.
11. Szczeklik A, Dworski R, Mastacaz L, Prokop A, Sheller JR, Nizankowska E, et al. Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. Am J Respir Crit Care Med 1998;158:1168-72.
12. Pennings HJ, Dentener MA, Buurman WA, Wouters EFM. Salbutamol and salmeterol moedulate cytokine production by peripheral blood monocytes. Eur Respir J 1995;8(suppl 19):1871.
13. 2-agonists: A comparison of salbutamol and salmeterol. Eur Respir J 1995;8(suppl 19):2692.
14. Oddera S, Silvestri M, Scraso L, Testi R, Rossi GA. Salmeterol inhibits the allergen-induced mononuclear cell proliferation and downregulates GM-CSF release and HLA-DR expression by monocytes. Pulm Pharmacol Ther 1997;10:43-9.
15. Joseph M, Tonnel AB, Capron A, Dessaint JP. The interaction of IgE anti-body with human alveolar macrophages and its participation in the inflammatory processes of lung allergy. Agents Actions 1981;11:619-22.
16. Baker AJ, Palmer J, Johnson M, Fuller RW. Inhibitory actions of salmeterol on human airway macrophages and blood monocytes. Eur J Pharmacol 1994;264:301-6.
17. Lundback B, Rawlinson DW, Palmer JBD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993;48:148.
18. Li D, Wang D, Venge P, Dahl R, Faurschou P, Jeffery P. Comparison of the antiinflammatory effects of inhaled fluticasone propionate and salmeterol in asthma: A placebo-controlled crossover study of bronchial biopsies. Eur Respir J 1997;10:444S.
19. Martin RJ, Cicutto LC, Smith HR, Ballard RD Szefler SJ. Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991;143:351-7.
20. Fabbri LM, Papi A, Boschetto P, Ciaccia A, Neutrophils in asthma. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Boston (MA): Black-welt Scientific Publications; 1995. p. 383-8.
21. Bloeman PGM, Van den Tweek MC, Henricks PAJ; et al. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 1997;272:L580-7.
22. Eda R, Tanimoto Y, Marou H, Bewtra AK, Townley RC. Comparison of effect of formoterol and salbutamol on human neutrophil function in vitro. Allergy 1997;91:301.
23. Ottonello L, Morone,P, Dapino P, Dallegri F, Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. Clin Exp Immunol 1996;106:97-102.
24. Ward C, Li X, Wang N, Zheng L, Bish R, Orsida B, et al. Salmeterol reduces BAL IL-8 levels in asthmatics on low dose inhaled corticosteroids. Eur Respir J 1998;12:380S.
25. Dentener MA, Buurman WA, Wouters EFM. Theophylline and the β-agonists salmeterol and salbutamol potently block neutrophil activation, as indicated by a reduced release of bacterial/permeability-increasing protein. Am J Respir Crit Care Med 1998;157:A602.
26. Anenden V, Egemba G, Kessel B, Johnson M, Costello J, Kilfeather S. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre- and post-antigen challenge. Eur Respir J 1998;12:157S.
27. Muñoz NM, Rabe KF, Vita AJ, et al. Paradoxical blockade of β adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. J Pharmacol Exp Ther 1995;273:850-4.
28. Volcheck GW, Gleich GJ, Kita H. Pro and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunol 1998;101:153.
29. Spoelstra FM, Berends C, Dijkhuizen B, de Monchy JG, Kauffman HF. Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils in vitro. Eur Respir J 1998;12:585-91.
30. 4 by human eosinophils. Eur Respir J 1996;9:141s-5s.
31. Weersink EJM, Aalbers R, Koeter GH, et al. Partial inhibition of the early and late asthmatic response by a single dose of salmeterol. Am J Respir Crit Care Med 1994;150:1262-7.
32. Faurschou P, Dahl R, Jeffery R, Venge P, Egerod I. Comparison of the anti-inflammatory effects of fluticasone and salmeterol in asthma: A placebo controlled, double blind, cross-over study with bronchoscopy, bronchial methacholine provocation and lavage. Eur Respir J 1997;10:243S.
33. Venge P, Dahl R, Faurschou P, Jeffery P. Comparison of the anti-inflammatory effects of fluticasone propionate and salmeterol in asthma: Eosinophil lumenal accumulation and mediator release. Eur Respir J 1997;10(suppl 25):445S.
34. Wallin A, Melander N, Sandstrom T, et al. 12 Months' treatment with inhaled formoterol twice daily in asthmatic patients. Am Rev Respir Dis 1990;141:A210.
35. Pedersen B, Dahl R, Venge P. The effect of salmeterol on the early and late phase reaction to bronchial allergen challenge and postchallenge variation in bronchial hyperractivity, blood eosinophils and serum eosinophil cationic protein. Am Rev Respir Dis 1991;143:A649.
36. Dente FL, Bartoli ML, Carnevali S, et al. Different effects of one single dose and one week treatment of salmeterol on allergen-induced asthmatic responses and increase of sputum eosinophils in mild asthmatics. Am J Respir Crit Care Med 1998;157:A819.
37. Sekut L, Champion BR, Page K, Menius JA Jr, Connolly KM. Anti-inflammatory activity of salmeterol: Down-regulation of cytokine production. Clin Exp Immunol 1995;99:461-6.
38. 2-adrenoceptor subtype. Am J Respir Cell Mol Biol 1998;19:400-7.
39. Oddera S, Sitvestri M, Scarso L, Balbi S, Quaglia R, Rossi GA. Salmeterol inhibits in vitro the allergen-induced proliferative response of peripheral blood T-lymphocytes. Am Rev Respir Dis 1993;147:A174.
40. Gratziou C, Roberts JA, Walls A, Holgate ST, Howarth P. Lymphocyte populations in BAL of asthmatics after salmeterol treatment. Eur Respir J 1992;5(suppl 15):207S.
41. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994;150:1006-11.
42. 2-adrenoceptor agonist, on IgE-mediated histamine release from human basophils. J Invest Allergol Clin Immunol 1994;4:12-7.
43. Gibbs BF, Vollrath IB, Albrecht C, Amon U, Wolff HH, Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs. Naunyn Schmiedebergs Arch Pharmacol 1998;357:573-8.
44. Sichletidlis L, Daskalopoulou E, Kyriazis G, Kosmidou I, Koupidou S, Pechlivanidis T, et al. Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma. J Int Med Res 1993;21:81-8.
45. Lebel B, Arnoux B, Chanez P, Bougeard YH, Daures JP, Bousquet J. et al. Ex vivo pharmacologic modulation of basophil histamine release in asthmatic patients. J Allergy Clin Immunol 1996;51:394-400.
46. 2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997;155:704-10.
47. 2-agonists and corticosteroids. Curr Allergy Clin Immunol 2002;15:16-22.
48. Usmani OS, Maneechotesuwan K, Adcock IM, Barnes PJ. Glucocorticoid receptor activation following inhaled fluticasone and salmeterol. Am J Respir Crit Care Med 2002;165:A616.
49. Korn S, Jerre A, Brattsand R. Additive inhibition of formoterol and budesonide on GMCSF expression in cultured bronchial epithelial cells. Am J Respir Crit Care Med 1999;159:A114.
50. 2-agonists and corticosteroids. FASEB J 2001;15:261-9.
51. Ziesche R, Block LH. Two different levels of action of salmeterol and glucocorticoids relevant for anti-inflammatory effects. Int Respir Forum 1995;3:67-8.
52. 2-agonists and corticosteroids on tumor necrosis factor alpha-induced interleukin-8 release from cultured human airway smooth muscle cells. Am J Respir Cell Mol Biol 2000;22:1-7.
53. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF. Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression on human lung fibroblasts. Eur Respir J 2000;15:68-71.
54. Pace E, Vignola AM. Increased T-lymphocyte apoptosis by the combination of salmeterol and fluticasone. Am J Respir Crit Care Med 2001;163:A188.
55. 2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999;160:1493-9.
56. Sue-Chu M, Wallin A, Wilson S, Ward J, Sandstrom T, Djukanovic R, et al. Bronchial biopsy study in asthmatics treated with low and high dose fluticasone propionate (FP) compared to low close FP combined with salmeterol. Eur Respir J 1999;14:124S.
57. 2-agonist over 3 months on airway wall remodelling in asthma. Am J Respir Crit Care Med 2001;164:117-21.